Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Renal Transplantation
You have accessRestricted Access

Inflammation in Renal Transplantation

Sadollah Abedini, Ingar Holme, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hans-Hellmut Neumayer, Carola Grønhagen-Riska, Patrice Ambühl, Hallvard Holdaas and ; on behalf of the ALERT study group
CJASN July 2009, 4 (7) 1246-1254; DOI: https://doi.org/10.2215/CJN.00930209
Sadollah Abedini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingar Holme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfried März
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisela Weihrauch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bengt Fellström
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Jardine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward Cole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart Maes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Hellmut Neumayer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carola Grønhagen-Riska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice Ambühl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hallvard Holdaas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Background and objectives: Renal transplant recipients experience premature cardiovascular disease and death. The association of inflammation, all-cause mortality, and cardiovascular events in renal transplant recipients has not been examined in a large prospective controlled trial.

Design, setting, participants, & measurements: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin on cardiovascular and renal outcomes in 2102 renal transplant recipients. Patients initially randomized to fluvastatin or placebo in the 5- to 6-yr trial were offered open-label fluvastatin in a 2-yr extension to the original study. The association between inflammation markers, high-sensitivity C-reactive protein (hsCRP), and IL-6 on cardiovascular events and all-cause mortality was investigated.

Results: The baseline IL-6 value was 2.9 ± 1.9 pg/ml (n = 1751) and that of hsCRP was 3.8 ± 6.7 mg/L (n = 1910). After adjustment for baseline values for established risk factors, the hazard ratios for a major cardiac event and all-cause mortality for IL-6 were 1.08 [95% confidence interval (CI), 1.01 to 1.15, P = 0.018] and 1.11 (95% CI, 1.05 to 1.18, P < 0.001), respectively. The adjusted hazard ratio for hsCRP for a cardiovascular event was 1.10 (95% CI, 1.01 to 1.20, P = 0.027) and for all-cause mortality was 1.15 (95% CI, 1.06 to 1.1.25, P = 0.049).

Conclusions: The inflammation markers IL-6 and hsCRP are independently associated with major cardiovascular events and all-cause mortality in renal transplant recipients.

Although cholesterol lowering therapy with statins has reduced the incidence of cardiac events in renal transplant recipients, premature cardiovascular events and premature death is still a major concern in this population (1,2). The prevalence of traditional cardiovascular risk factors cannot fully explain the increased incidence of cardiovascular events, and several reports have emphasized the role of nontraditional cardiovascular risk factors (3,4).

Inflammation and activation of the immune system may play important roles in atherogenesis (5,6). Cytokines induce production of IL-6 from various tissues, including the liver, and increase downstream mediators such as C-reactive protein (CRP) (7). Renal transplant recipients, by the process of receiving an allograft, have an additional activation of their immune system (8–11).

In the general population, CRP is regarded as a risk factor for cardiovascular events and all-cause mortality (12,13). In patients without hyperlipidemia but with elevated high-sensitivity CRP (hsCRP), it was recently demonstrated that rosuvastatin significantly reduced the incidence of major cardiovascular events (14).

In patients with chronic renal failure, an association between malnutrition, inflammation, and atherosclerosis has been demonstrated (15). In dialysis patients CRP has been shown to be a marker of all-cause and cardiovascular death (16). It has also been speculated that the better graft survival achieved with preemptive transplantation might be due to less exposure to inflammation markers associated with dialysis (17,18). In renal transplant recipients there are few studies examining the association between inflammatory markers and all-cause mortality, cardiac events, or cerebrovascular events. A small cross-sectional study indicated that renal transplant patients with cardiovascular disease (CVD) had higher CRP than patients without CVD (19). Another retrospective study indicated that elevated pretransplant CRP was associated with all-cause and cardiovascular mortality (20). Ducloux et al. followed a small cohort of renal transplant patients and reported that elevated CRP predicted coronary events (21). In a prospective registry-based study, Winkelmayer and colleagues showed that kidney transplant patients with a CRP above 5 mg/dl had an increased mortality compared with patients below that threshold (22), and in a subsequent follow-up paper the authors demonstrated a J-shaped association between hsCRP (below 5 mg/L) and mortality (23). There are no reports of assessment of an association between hsCRP and/or IL-6 and major cardiovascular events or all-cause mortality in prospectively controlled trials in renal transplant patients. We therefore performed a post hoc analysis of the ALERT trial examining the predictive value of the inflammation markers hsCRP and IL-6 for cardiovascular events and all-cause mortality in renal transplant recipients.

Materials and Methods

Study Design

The ALERT study design and baseline data have been described previously (1). Briefly, ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin, 40 to 80 mg daily, on cardiovascular and renal outcomes in renal transplant recipients over a follow-up period of 5 to 6 yr. Eligible patients were men and women aged 30 to 75 yr who had received a renal transplant more than 6 mo before enrolment and with a total serum cholesterol concentration between 4.0 and 9.0 mmol/L (155 to 348 mg/dl). Patients with a history of myocardial infarction more than 6 mo before randomization could be enrolled if their total cholesterol levels ranged from 4.0 to 7.0 mmol/L (155 to 270 mg/dl). Of 1787 patients who completed ALERT, 1652 (92%) accepted open-label fluvastatin, 80 mg daily, in a 2-yr extension of the original study. Mean total follow-up time in the extension study was 6.7 yr. The study adhered to the International Conference on Harmonization guidelines for Good Clinical Practice and in accordance with the Declaration of Helsinki. All participants provided written informed consent, and the ethics committee at each participating center approved the trial.

Study patients were seen at 1.5 mo after randomization and at 6-mo intervals thereafter. Clinical status was assessed at each visit. Laboratory measurements of lipids, serum creatinine, creatine kinase, and hepatic enzymes were performed at a central laboratory (CRL, Medinet, Breda, The Netherlands).

IL-6 was measured by a human IL-6 immunoassay (R&D Systems, Inc., Minneapolis, MN, USA) and hsCRP by using an immunoturbometric analysis (Roche Diagnostics GmbH, Mannheim, Germany). Measurements of IL-6 and hsCRP were performed on blood samples at baseline and were not followed longitudinally during the study.

An independent critical events committee blinded to treatment assignment reviewed all primary and secondary endpoints for adjudication. All analyses were based on the committee's classification of endpoints, which was agreed on by consensus or by majority.

Statistical Analyses

SPSS version 16.0 (SPSS, Inc.) was used for statistical analyses. For normally distributed variables, mean, and SD are presented. hsCRP and IL-6 values were not normally distributed and showed a marked tail to the right. Logarithmic transformation showed a strictly bell shaped distribution of both variables and these transformed values were used for the statistical analysis. A Cox proportional hazard model was used to analyze the relationship between risk factors and time to event for all endpoints. All covariates were carefully examined and fulfilled assumptions of proportionality of hazard ratios in the Cox hazard models. Univariate and multivariate analysis were then carried out to study how risk factors associated with the risk of all-cause mortality, major cardiac events (MACE), and cerebrovascular (CBV) events. Corresponding hazard ratios for group comparisons were calculated with 95% confidence limits.

Results

Baseline Characteristics

Basic patient and demographic data in ALERT and the ALERT extension have been previously published (2). Patients were transplanted at a mean of 4.5 yr before randomization into the trial. Both treatments groups in the ALERT trial were well balanced with regard to baseline demographics and renal characteristics.

In this post hoc analysis, we separated the patients into those with available baseline hsCRP and IL-6 values. The patients’ demographic characteristics based on this separation are summarized in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Patients demographic and baseline characteristics in patients with available baseline hsCRP and IL-6a

The number of patients with hsCRP (n = 1910) and IL-6 (n = 1751) at baseline differed, and baseline data are therefore shown separately for each cohort. However, baseline characteristics between the two cohorts were practically identical. There were no differences in proportion of patients with diabetes, coronary heart disease, current smokers, and transplant type between the groups (Table 1). hsCRP and IL-6 were correlated (r = 0.332, P < 0.001).

Endpoints

hsCRP and IL-6 increased with increasing body mass index (BMI) and both were significantly correlated with BMI (r = 0.18, P < 0.001). However, BMI was not a significant risk factor for all-cause death and MACE in univariate analysis.

Further analysis by Kaplan–Meier survival method did not show any significant differences in occurrence of all-cause death or MACE by stratifying patients by BMI (normal BMI 18.5 to 25, n = 890, 46%; overweight BMI 25 to 30, n = 684, 35%; obese BMI ≥ 30, n = 268, 14%).

In the hsCRP cohorts, there were 176 CBV events, 287 cardiac events, and 354 deaths. Corresponding numbers for the IL-6 cohort were 166, 255, and 308, respectively. The prevalence of the study endpoints within the quartiles of hsCRP and IL-6 are summarized in Table 2 a and b, and demonstrate a comparable incidence of all-cause mortality and MACE.

View this table:
  • View inline
  • View popup
Table 2a.

Occurrence of all-cause death, MACE, and CBV events by quartiles of hsCRPa

View this table:
  • View inline
  • View popup
Table 2b.

Occurrence of all-cause death, MACE, and CBV events by quartiles of IL-6a

In both cohorts of patients there were significantly more cardiovascular events and all-cause death in the fourth quartile compared with the first quartile, with the exception of CBV events in the hsCRP cohort. We also performed separate analyses for deaths in patients with a baseline hsCRP below 5 mg/L (23), and we divided this population in quartiles (Figure 1d). Also in this subset of patients there was a successive increase in deaths by increasing hsCRP quartiles. There was a consistent increase in all endpoints from first to fourth quartile.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Association between (A) all-cause death, (B) major cardiovascular events, and (C) cerebrovascular events for quartiles of high-sensitivity C-reactive protein (hsCRP) over the whole range of hsCRP. (D) Association between all-cause death, (E) major cardiovascular events, and (F) cerebrovascular events for quartiles of hsCRP below 5 mg/dl. x-axis represents follow-up time in years. y-axis represents cumulative survival.

Risk Factor Analyses

Exploratory risk factor analysis was carried out on many potentially important risk factors for all-cause death, MACE, and CBV events (Tables 3⇓⇓ and 4⇓⇓).

View this table:
  • View inline
  • View popup
Table 3a.

Hazard ratios for all-cause mortality by univariate and multivariate Cox regression in the hsCRP cohorta

View this table:
  • View inline
  • View popup
Table 3b.

Hazard ratios for MACE by univariate and multivariate Cox regression in the hsCRP cohorta

View this table:
  • View inline
  • View popup
Table 3c.

Hazard ratios for CBV events by univariate and multivariate Cox regression in the hsCRP cohorta

View this table:
  • View inline
  • View popup
Table 4a.

Hazard ratios for all-cause death by univariate and multivariate Cox regression in the IL-6 cohorta

View this table:
  • View inline
  • View popup
Table 4b.

Hazard ratios for MACE by univariate and multivariate Cox regression in the IL-6 cohorta

View this table:
  • View inline
  • View popup
Table 4c.

Hazard ratios for all type of CBV events by univariate and multivariate Cox regression in the IL-6 cohorta

On the basis of univariate analysis using Cox regression, diabetes mellitus, smoking, previous coronary heart disease, hsCRP, age, serum creatinine, and systolic blood pressure (BP), were significant risk factors for all causes of death and MACE in the hsCRP cohort. Gender and LDL cholesterol were significant univariate risk factors for MACE but not for all-cause death in the hsCRP cohort.

For all types of CBV events, diabetes mellitus, previous coronary heart disease, age, and systolic BP were significant univariate risk factors.

On the basis of multivariate Cox regression including all of the above risk factors, diabetes mellitus, smoking, age, previous coronary heart disease, hsCRP, and serum creatinine were significant for all causes of death and MACE in the hsCRP cohort, but LDL cholesterol was only a significant risk factor for MACE in the hsCRP cohort. Smoking was a significant risk factor for CBV events in multivariate analysis, but IL-6 and systolic BP were no longer significant risk factors for CBV events. Risk factors for all-cause death, MACE, and CBV events in the IL-6 cohort were very much the same as in the hsCRP cohort, with small differences in the size of the hazard ratios.

Hazard ratios for the different univariate and multivariate risk factors for all-cause death, MACE, and CBV events did not differ substantially for the two cohorts (Tables 3⇑⇑ and 4⇑⇑).

Kaplan–Meier survival curves show associations between all-cause death, MACE, and CBV events and hsCRP values within the hsCRP quartiles (Figures 1A through 1C). Risk of death, MACE, and CBV events increased significantly with increasing hsCRP quartiles not only in the continuous range of hsCRP values but also in the increasing quartile for hsCRP values below 5.0 mg/L (Figures 1D through 1F).

The Kaplan–Meier survival curves by quartiles of IL-6 (Figures 2A through 2C) were comparable to the hsCRP curves in Figures 1A through 1C.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Association between (A) all-cause death, (B) major cardiovascular events, and (C) cerebrovascular events with IL-6 for quartiles of IL-6. x-axis represents follow-up time in years. y-axis represents cumulative survival.

Discussion

In this post hoc analysis, we have shown that the inflammatory markers hsCRP and IL-6, adjusted for traditional risk factors, are predictive for future cardiovascular events and all-cause mortality in renal graft recipients. Although hsCRP and IL-6 are correlated, the observation that both markers were predictive for outcome parameters strengthens the notion that inflammation is an important risk factor for cardiovascular events and all-cause mortality in renal transplant patients.

Our data support previous observational and/or registry data that have indicated that CRP is associated with cardiovascular events and/or all-cause mortality in renal transplant recipients (19–23) and in the general population (5,6,12,13)

In hemodialysis and peritoneal dialysis patients (24–26) and also in the general population, an association between IL-6 and cardiovascular morbidity and mortality has been established (13,27). No trial has examined the association of IL-6 with all-cause mortality or cardiovascular events in renal transplant patients. The data from this analysis demonstrate that the association of IL-6 with cardiovascular events and all-cause mortality also extends to renal transplant patients.

Vascular inflammation is an important factor in the pathogenesis of atherosclerosis in renal transplant recipients (8–11), whereas genetically based elevation in CRP is not associated with posttransplant morbidity and mortality (28), as also shown for the general population (29,30).

In the adult nontransplanted population, the American Heart Association and the Centers for Disease Control and Prevention have endorsed three cutoff points for CRP: <1 mg/dl, low risk; 1 to 3 mg/dl, average risk; and >3 mg/L, high risk (31). By this definition, the overall population in ALERT is in the moderate to high-risk end. The IL-6 data are more difficult to assess across diverse populations because of lack of standardized methods (31). However, in the posttransplant recipients, the inflammatory markers CRP and IL-6 have been reported to be elevated in most studies on renal transplant recipients (19,21–23,32–36), although they are lower than pretransplant values (37).

By dichotomizing the CRP at 0.5 mg/dl, Winkelmayer et al. showed that renal transplant patients above that level had a 53% increased mortality risk compared with patients with a CRP below the threshold (22). In a subsequent paper, Winkelmayer and colleagues demonstrated a J-shaped association between hsCRP and mortality in kidney transplant recipients when dividing hsCRP values into quartiles for values below 5 mg/L. Patients in the lowest quartile (quartile 1) had an increased mortality risk of about two-fold compared with the chosen reference of quartile 2. There is a linear relationship between CRP and mortality in the general population (12,38) and in the dialysis population (15,16). No J-shaped curves for mortality have been demonstrated in nonrenal (39) or in dialysis patients (40) for the companion inflammation marker IL-6.

We performed detailed statistical analyses over the whole range of hsCRP values and a separate analysis for hsCRP below 5 mg/L. None of these analyses revealed a J-shaped curve for the association of mortality and hsCRP. Repeating these analyses using IL-6 also indicated no J-shaped curve for mortality. The reason for the difference in results is unclear; however, we believe that the data from our trial are more robust because we do have 354 fatal events with a follow-up time of 6.7 yr within the hsCRP cohort.

Inflammatory markers CRP and IL-6 are associated with diabetes mellitus, insulin resistance, obesity, and adipose tissue (41). Our findings also suggest that higher BMI is associated with increased values of inflammatory markers in transplant patients, but BMI was not a significant risk factor for all-cause death or MACE.

The dialysis population is characterized by a status of high inflammation, and an inverse relationship between cholesterol and all-cause mortality has been shown (15,42). However, when corrected for inflammation the usual association for cholesterol and cardiovascular outcome is evident (43). In two recent trials in hemodialysis patients, 4D and Aurora, the inflammation marker hsCRP was significantly associated with increased risk for cardiovascular endpoints (44,45). However, although statin treatment in both trials significantly reduced in LDL cholesterol and hsCRP, the trials failed to show a reduction in the primary cardiovascular endpoints. The findings from these two trials might indicate that inflammation markers in patients receiving hemodialysis differ from other populations, including the renal transplant patients (44,46)

Potential limitations of our study merit consideration. First, this analysis was a post hoc analysis of the ALERT extension trial. IL-6 and hsCRP were not available for all patients at baseline, but baseline demographic data of those with or without inflammation analyzed were not different. The strengths of the study are the many patients followed for an extended period and the independent adjudication of predefined outcome parameters.

Renal transplant recipients are at high risk of for premature CVD, which is the leading cause of death in patients with a functional renal graft (3,47). We have previously shown that long-term statin treatment reduces MACE in this population (1,2). However, despite lipid-lowering there is considerable residual risk for cardiovascular events in renal transplant recipients. This might indicate that current management of kidney transplant recipients fails to utilize optimal cardiovascular risk reduction strategies. There is a pressing need to explore the role of other classical and novel cardiovascular risk factors in this population. Adding markers of inflammation such as hsCRP might be helpful to identify high-risk patients.

In conclusion, the inflammatory markers hsCRP and IL-6 may be predictive for future cardiovascular events and all-cause mortality in renal transplant recipients. These parameters should be considered in the design of future intervention trials.

Disclosures

Novartis Pharma supported the ALERT core (Lancet 36: 2024–2031, 2003) and the extension study (Am J Transplant 5: 2929–2936, 2005) by a research grant. This analysis was not supported

Dr. Fellstrøm reports receiving consulting fees from AstraZeneca, Novartis, Roche, and Wyeth; lecture fees from Astellas, Novartis, and Roche; grant support from Novartis, Roche, Merck-Schering-Plough, and Wyeth; and serving as a national coordinator for the Study of Heart and Renal Protection (SHARP) study at Oxford University's Trial Service Unit. Dr. Jardine has received consulting fees from Novartis, AstraZeneca, and Wyeth, and lecture fees from Novartis and Astellas. Dr. Holdaas has received consulting fees from Novartis, AstraZeneca, and Roche; lecture fees from Novartis, AstraZeneca, and Roche; and serves as a regional coordinator for the SHARP study. Ingar Holme reports receiving steering committee honorarium from Merck, Roche, and Pfizer, and consultancy honorariums from AstraZeneca and Merck. Dr. März reports receiving consulting fees from Astra-Zeneca and Pfizer; lecture fees from Astellas, Astra-Zeneca, Merck-Schering-Plough, Pfizer, and Roche; and grant support from Aventis, Pfizer, Roche, and Siemens. Drs Abedini, Cole, Maes, Weihrauch, Neumayer, Ambüh, and Grønhagen-Riska report no conflict of interest.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Access to UpToDate on-line is available for additional clinical information at http://www.cjasn.org/

  • Received February 10, 2009.
  • Accepted May 6, 2009.
  • Copyright © 2009 by the American Society of Nephrology

References

  1. ↵
    Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet361 :2024– 2031,2003
    OpenUrlCrossRefPubMed
  2. ↵
    Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant5 :2929– 2936,2005
    OpenUrlCrossRefPubMed
  3. ↵
    Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol11 :1735– 1743,2000
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Rigatto C, Parfrey P: Therapy insight: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol2 :514– 526,2006
    OpenUrlCrossRefPubMed
  5. ↵
    Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol12 :1549– 1557,2001
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation109 :II2– II10,2004
    OpenUrlCrossRefPubMed
  7. ↵
    Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med352 :1685– 1695,2005
    OpenUrlCrossRefPubMed
  8. ↵
    Vazquez MA, Jeyarajah DR, Kielar ML, Lu CY: Long-term outcomes of renal transplantation: A result of the original endowment of the donor kidney and the inflammatory response to both alloantigens and injury. Curr Opin Nephrol Hypertens9 :643– 648,2000
    OpenUrlCrossRefPubMed
  9. Cottone S, Palermo A, Vaccaro F, Mule G, Guarneri M, Arsena R, Vadala A, Cerasola G: Inflammation and endothelial activation are linked to renal function in long-term kidney transplantation. Transpl Int20 :82– 87,2007
    OpenUrlCrossRefPubMed
  10. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J, Sukhova G, Witztum JL, Sharpe AH, Lichtman AH: Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation114 :2047– 2055,2006
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Martinez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Seron D, Cruzado JM, Moreso F, Diez-Noguera A, Grinyo JM: Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. Transplant Proc37 :3788– 3790,2005
    OpenUrlCrossRefPubMed
  12. ↵
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med336 :973– 979,1997
    OpenUrlCrossRefPubMed
  13. ↵
    Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med351 :2599– 2610,2004
    OpenUrlCrossRefPubMed
  14. ↵
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med359 :2195– 2207,2008
    OpenUrlCrossRefPubMed
  15. ↵
    Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int55 :1899– 1911,1999
    OpenUrlCrossRefPubMed
  16. ↵
    Wanner C, Zimmermann J, Schwedler S, Metzger T: Inflammation and cardiovascular risk in dialysis patients. Kidney Int61 :S99– S102.2002
    OpenUrlCrossRefPubMed
  17. ↵
    Lauzurica R, Pastor MC, Bayes B, Hernandez JM, Bonet J, Dolade M, Navarro M, Romero R: Pretransplant inflammation: A risk factor for delayed graft function? J Nephrol21 :221– 228,2008
    OpenUrlPubMed
  18. ↵
    Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med344 :726– 731,2001
    OpenUrlCrossRefPubMed
  19. ↵
    Bakri RS, Afzali B, Covic A, Sriskantharan R, Bharma-Ariza P, Park WH, Sriharan M, Dalton N, Wierzbicki AS, Crook MA, Goldsmith DJ: Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clin Transplant18 :201– 204,2004
    OpenUrlCrossRefPubMed
  20. ↵
    Varagunam M, Finney H, Trevitt R, Sharples E, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM: Pretransplantation levels of C-reactive protein predict all-cause and cardiovascular mortality, but not graft outcome, in kidney transplant recipients. Am J Kidney Dis43 :502– 507,2004
    OpenUrlCrossRefPubMed
  21. ↵
    Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int66 :441– 447,2004
    OpenUrlCrossRefPubMed
  22. ↵
    Winkelmayer WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant4 :1148– 1154,2004
    OpenUrlCrossRefPubMed
  23. ↵
    Winkelmayer WC, Schaeffner ES, Chandraker A, Kramar R, Rumpold H, Sunder-Plassmann G, Fodinger M: A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transpl Int20 :505– 511,2007
    OpenUrlCrossRefPubMed
  24. ↵
    Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int18 :387– 394,1998
    OpenUrlAbstract/FREE Full Text
  25. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int61 :S103– S108,2002
    OpenUrlCrossRef
  26. ↵
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int55 :648– 658,1999
    OpenUrlCrossRefPubMed
  27. ↵
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med347 :1557– 1565,2002
    OpenUrlCrossRefPubMed
  28. ↵
    Kruger B, Boger CA, Schroppel B, Farkas S, Schnitzbauer AA, Hoffmann U, Obed A, Murphy BT, Banas B, Kramer BK: No effect of C-reactive protein (CRP) haplotypes on CRP levels and post-transplant morbidity and mortality in renal transplantation. Transpl Int21 :452– 458,2008
    OpenUrlCrossRefPubMed
  29. ↵
    Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG: Genetically Elevated C-reactive protein and ischemic vascular disease. N Engl J Med359 :1897– 1908,2008
    OpenUrlCrossRefPubMed
  30. ↵
    Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey SG: C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet366 :1954– 1959,2005
    OpenUrlCrossRefPubMed
  31. ↵
    Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, III, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107 :499– 511,2003
    OpenUrlFREE Full Text
  32. ↵
    Kusec V, Smalcelj R, Puretic Z, Szekeres T: Interleukin-6, transforming growth factor-beta 1, and bone markers after kidney transplantation. Calcif Tissue Int75 :1– 6,2004
    OpenUrlPubMed
  33. Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A: Elevated serum interleukin-6 (IL-6) in solid-organ transplant recipients is positively associated with tissue destruction and IL-6 gene expression in the periodontium. J Periodontol77 :1871– 1878,2006
    OpenUrlCrossRefPubMed
  34. Sezer S, Akcay A, Ozdemir FN, Kulah E, Arat Z, Haberal M: Post-transplant C-reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant18 :722– 725,2004
    OpenUrlCrossRefPubMed
  35. van Ree RM, Oterdoom LH, de Vries AP, Gansevoort RT, van der Heide JJ, van Son WJ, Ploeg RJ, de Jong PE, Gans RO, Bakker SJ: Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients. Nephrol Dial Transplant22 :246– 253,2007
    OpenUrlCrossRefPubMed
  36. ↵
    Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L, Gonzalez-Tableros N, Martin-del-Campo F, Correa-Rotter R, Valera I, Alberu J: Markers of inflammation before and after renal transplantation. Transplantation80 :47– 51,2005
    OpenUrlCrossRefPubMed
  37. ↵
    Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, Ikizler TA, Himmelfarb J: Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation79 :914– 919,2005
    OpenUrlCrossRefPubMed
  38. ↵
    Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation109 :1955– 1959,2004
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med106 :506– 512,1999
    OpenUrlCrossRefPubMed
  40. ↵
    Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis32 :107– 114,1998
    OpenUrlCrossRefPubMed
  41. ↵
    Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol19 :972– 978,1999
    OpenUrlAbstract/FREE Full Text
  42. ↵
    Lowrie EG, Lew NL: Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk. Semin Nephrol12 :276– 283,1992
    OpenUrlPubMed
  43. ↵
    Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA291 :451– 459,2004
    OpenUrlCrossRefPubMed
  44. ↵
    Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med360 :1395– 1407,2009
    OpenUrlCrossRefPubMed
  45. ↵
    Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med353 :238– 248,2005
    OpenUrlCrossRefPubMed
  46. ↵
    Krane V, Winkler K, Drechsler C, Lilienthal J, Marz W, Wanner C: Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int74 :1461– 1467,2008
    OpenUrlCrossRefPubMed
  47. ↵
    Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease—Major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation60 :451– 457,1995
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 4, Issue 7
July 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Inflammation in Renal Transplantation
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inflammation in Renal Transplantation
Sadollah Abedini, Ingar Holme, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hans-Hellmut Neumayer, Carola Grønhagen-Riska, Patrice Ambühl, Hallvard Holdaas
CJASN Jul 2009, 4 (7) 1246-1254; DOI: 10.2215/CJN.00930209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Inflammation in Renal Transplantation
Sadollah Abedini, Ingar Holme, Winfried März, Gisela Weihrauch, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hans-Hellmut Neumayer, Carola Grønhagen-Riska, Patrice Ambühl, Hallvard Holdaas
CJASN Jul 2009, 4 (7) 1246-1254; DOI: 10.2215/CJN.00930209
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Proteins in Preservation Fluid as Predictors of Delayed Graft Function in Kidneys from Donors after Circulatory Death
  • Donor-Recipient Weight and Sex Mismatch and the Risk of Graft Loss in Renal Transplantation
  • A Case-Based Analysis of Whether Living Related Donors Listed for Transplant Share ESRD Causes with Their Recipients
Show more Renal Transplantation

Cited By...

  • Circulating Advanced Glycation Endproducts and Long-Term Risk of Cardiovascular Mortality in Kidney Transplant Recipients
  • Participant acceptability of exercise in kidney disease (PACE-KD): a feasibility study protocol in renal transplant recipients
  • Interferon-{gamma}-Mediated Allograft Rejection Exacerbates Cardiovascular Disease of Hyperlipidemic Murine Transplant Recipients
  • Rosuvastatin in Diabetic Hemodialysis Patients
  • A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire